Generic placeholder image

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery

Editor-in-Chief

ISSN (Print): 1872-2148
ISSN (Online): 2212-3334

Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications

Author(s): Sanjay Kalra, Ambika G. Unnikrishnan, Navneet Agrawal and Anupam K. Singh

Volume 5, Issue 3, 2011

Page: [197 - 202] Pages: 6

DOI: 10.2174/187221411797265926

Price: $65

Abstract

The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. These agents may be used either as monotherapy for the treatment of type-2 diabetes or in combination with other anti-diabetic drugs. The present review highlights the use of linagliptin and other new (DPP-4) inhibitors in the management of type-2 diabetes. The review also highlights advantages, comparative pharmacokinetic, safety profile and other potential uses including potential newer indications of DPP-4 inhibitors and relevant patents. The other potential uses that are not restricted to diabetes include obesity, cardiovascular disease, neurological disease, hepatobiliary disease, wound healing, and other inflammatory illnesses.

Keywords: Diabetes, Pharmacokinetics, placebo, DPP4 inhibitors, hepatic safety, incretins, linagliptin, oral hypoglycemics, multiple sclerosis, renal safety


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy